Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [913]

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy ( Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China )

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy...

Prof Jair Bar - Sheba Medical Center, Tel-Aviv, Israel

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer ( Prof Jair Bar - Sheba Medical Center, Tel-Aviv, Israel )

Avelumab plus platinum-based chemotherapy may show some efficacy in patients...

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Avelumab plus platinum-based chemotherapy may show some efficacy in patients with extensive-stage small cell lung cancer ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

Avelumab combined with regorafenib shows improved outcome in solid tumours with...

Prof Antoine Italiano - Institute Bergonié, Bordeaux, France

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures ( Prof Antoine Italiano - Institute Bergonié, Bordeaux, France )

Blood test may identify patients with non-small cell lung cancer subtype who...

Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy ( Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA )

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows...

Dr Yan Zhang - Sichuan University, Chengdu, China

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC ( Dr Yan Zhang - Sichuan University, Chengdu, China )

Twice-daily chemoradiation remains the standard of care in limited stage small...

Dr Gerard Walls - Queen's University Belfast, Belfast, Northern Ireland

Twice-daily chemoradiation remains the standard of care in limited stage small-cell lung cancer ( Dr Gerard Walls - Queen's University Belfast, Belfast, Northern Ireland )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

What's new on ADCs in management of advanced NSCLC

Dr David Planchard - Institute Gustave Roussy, Villejuif, France

What's new on ADCs in management of advanced NSCLC ( Dr David Planchard - Institute Gustave Roussy, Villejuif, France )

Treatment of metastatic NSCLC without PD-L1 expression and without oncogene...

Dr Antonio Passaro - European Institute of Oncology, Milan, Italy

Treatment of metastatic NSCLC without PD-L1 expression and without oncogene addiction ( Dr Antonio Passaro - European Institute of Oncology, Milan, Italy )

ESMO 2023: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

More from ecancer